The American Journal of Digestive Diseases

, Volume 3, Issue 1, pp 12–23 | Cite as

Hexocyclium methosulfate in active duodenal ulcer

Evaluation of a new anticholinergic drug in conventional and long-acting forms, especially its effect on gastric pH as studied in 48-hour analysis
  • Anthony M. Kasich
  • Harry D. Fein
Article

Summary and conclusions

A study of hexocyclium, a new anticholinergic drug, has been reported.

1. After a control period, hexocyclium was administered in both conventional and long-acting forms to 28 patients with active duodenal ulcers. The pH of hourly samples of gastric secretion was determined, and was definitely higher when hexocyclium was administered. The long-acting form of the drug produced a more sustained effect than the conventional form.

2. At present, 57 patients with duodenal ulcer are under active treatment with hexocyclium, and control of their symptoms is satisfactory. Side effects have been minor. No treatment has had to be discontinued, and in only two instances has the dosage been reduced.

3. Hexocyclium is effective for the control of cramps and diarrhea in cases of irritable bowel syndrome.

There is a definite place for a long-acting anticholinergic drug, such as long-acting hexocyclium, in the over-all treatment of peptic ulcer. It is emphasized, however, that anticholinergic medication should not be used in place of other ulcer therapy, but rather as an important adjunct to diet and antacids, especially at night.

Keywords

Public Health Diarrhea Irritable Bowel Syndrome Peptic Ulcer Active Treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    James, A. H., andPickering, G.W. The role of gastric acidity in the pathogenesis of peptic ulcer.Clin. Sc. 8:181, 1949.Google Scholar
  2. 2.
    Watkinson, G. A study of the changes in pH of gastric contents in peptic ulcer using the twenty-four hour test meal.Gastroenterology 18:377, 1951.PubMedGoogle Scholar
  3. 3.
    Ivy, A. C., Grossman, M. I., andBachrach, W. H. Peptic Ulcer. Philadelphia, Blakiston, 1950.a, p. 877;b, p. 77.Google Scholar
  4. 4.
    Freezer, C. R. E., Gibson, C. S., andMatthews, E. A contribution to the study of “alkalis” as therapeutic agents.Guy's Hosp. Rep. 78:191, 1928.Google Scholar
  5. 5.
    Fischer, A. Growth of fibroblasts and hydrogen ion concentration of the medium.J. Exper. Med. 34:447, 1921.Google Scholar
  6. 6.
    Kirsner, J. B., Levin, E., andPalmer, W. L. Pamine bromide: Gastric antisecretory effects and therapeutic usefulness in peptic ulcer and other gastrointestinal disorders.Gastroenterology 26:852, 1954.PubMedGoogle Scholar
  7. 7.
    Roth, J. L. A., Wechsler, R. L., andBockus, H. L. Hazards in the use of anticholinergic drugs in the management of peptic ulcer disease.Gastroenterology 31:493, 1956.PubMedGoogle Scholar
  8. 8.
    Grimson, K. S. A clinical trial of Banthine in cases of peptic ulcer.Gastroenterology 14:583, 1950.PubMedGoogle Scholar
  9. 9.
    Rogers, M. P., andGray, C. L. A new anti-ulcer drug; A clinical and radiological evaluation.Am. J. Digest. Dis. 19:180, 1952.PubMedGoogle Scholar
  10. 10.
    Hollander, F. What constitutes effective neutralization of gastric contents?Am. J. Digest. Dis. 6:127, 1939.Google Scholar
  11. 11.
    Kirsner, J. B., andPalmer, W. L. The effect of various antacids on the hydrogenion concentration of the gastric contents.Am. J. Digest. Dis. 7:85, 1940.Google Scholar

Copyright information

© Paul B. Hoeber, Inc. 1958

Authors and Affiliations

  • Anthony M. Kasich
    • 1
  • Harry D. Fein
    • 1
  1. 1.New York 21

Personalised recommendations